Oligometastatic Prostate Cancer Treatment Outcomes from a Multicenter Study

160 patients with oligometastatic prostate cancer were analyzed in a multicenter retrospective study from May 2010 to May 2023. The data compares perioperative and oncological outcomes for two treatment groups: neoadjuvant hormonal therapy plus surgery versus surgery alone.

Use Cases

• Compare operative time and blood loss metrics between the NHT and standard therapy groups.
• Analyze positive surgical margin rates and pathological downstaging in T-stage across treatment cohorts.
• Model biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) outcomes.
• Investigate interaction effects between NHT and biopsy Gleason score ≥8 or clinical T stage ≥ T3 on survival.
• Assess the frequency of subsequent treatments and ADT-related adverse events post-intervention.

Strengths

• Data from 160 patients across five medical centers provides a multi-institutional perspective.
• Study spans a 13-year period from May 2010 to May 2023.
• Includes detailed comparison of two distinct treatment protocols with 80 patients in each group.
• Reports multiple clinical endpoints: surgical metrics, pathological findings, and three survival measures (bPFS, rPFS, OS).

Limitations

• Small sample size of 160 total patients limits statistical power for subgroup analyses.
• Retrospective study design is susceptible to selection bias and confounding factors.
• Data is contained in a DOCX file, requiring manual extraction for computational analysis.

Provenance

Source

figshare, authored by Yujie Dong.

Collection Method

Multicenter retrospective study.

Time Range

May 2010 to May 2023.

Freshness

null

Geography

Five Chinese medical centers.